Search Results - "Broekmans, Marloes"

Functional MYCN signature predicts outcome of neuroblastoma irrespective of MYCN amplification by Valentijn, Linda J, Koster, Jan, Haneveld, Franciska, Aissa, Rachida Ait, van Sluis, Peter, Broekmans, Marloes E. C, Molenaar, Jan J, van Nes, Johan, Versteeg, Rogier

“…Neuroblastoma is a pediatric tumor of the sympathetic nervous system. MYCN (V-myc myelocytomatosis viral-related oncogene, neuroblastoma derived [avian]) is…”
Get full text

Monocytes and Granulocytes Reduce CD38 Expression Levels on Myeloma Cells in Patients Treated with Daratumumab by Krejcik, Jakub, Frerichs, Kris A, Nijhof, Inger S, van Kessel, Berris, van Velzen, Jeroen F, Bloem, Andries C, Broekmans, Marloes E C, Zweegman, Sonja, van Meerloo, Johan, Musters, René J P, Poddighe, Pino J, Groen, Richard W J, Chiu, Christopher, Plesner, Torben, Lokhorst, Henk M, Sasser, A Kate, Mutis, Tuna, van de Donk, Niels W C J

“…Daratumumab treatment results in a marked reduction of CD38 expression on multiple myeloma cells. The aim of this study was to investigate the clinical…”
Get full text

A NOTCH feed-forward loop drives reprogramming from adrenergic to mesenchymal state in neuroblastoma by van Groningen, Tim, Akogul, Nurdan, Westerhout, Ellen M., Chan, Alvin, Hasselt, Nancy E., Zwijnenburg, Danny A., Broekmans, Marloes, Stroeken, Peter, Haneveld, Franciska, Hooijer, Gerrit K. J., Savci-Heijink, C. Dilara, Lakeman, Arjan, Volckmann, Richard, van Sluis, Peter, Valentijn, Linda J., Koster, Jan, Versteeg, Rogier, van Nes, Johan

“…Transition between differentiation states in development occurs swift but the mechanisms leading to epigenetic and transcriptional reprogramming are poorly…”
Get full text

T cell characteristics impact response and resistance to T cell-redirecting bispecific antibodies in multiple myeloma by Verkleij, Christie P M, O'Neill, Chloe A, Broekmans, Marloes E C, Frerichs, Kristine A, Bruins, Wassilis S C, Duetz, Carolien, Kruyswijk, Sandy, Baglio, Serena R, Skerget, Sheri, Montes de Oca, Rocio, Zweegman, Sonja, Verona, Raluca I, Mutis, Tuna, van de Donk, Niels W C J

“…Bispecific antibodies (BsAbs) directed against B-cell maturation antigen (BCMA; teclistamab) or the orphan G protein-coupled receptor GPRC5D (talquetamab)…”
Get full text

Preclinical activity and determinants of response of the GPRC5DxCD3 bispecific antibody talquetamab in multiple myeloma by Verkleij, Christie P.M., Broekmans, Marloes E.C., van Duin, Mark, Frerichs, Kristine A., Kuiper, Rowan, de Jonge, A. Vera, Kaiser, Martin, Morgan, Gareth, Axel, Amy, Boominathan, Rengasamy, Sendecki, Jocelyn, Wong, Amy, Verona, Raluca I., Sonneveld, Pieter, Zweegman, Sonja, Adams, Homer C., Mutis, Tuna, van de Donk, Niels W.C.J.

“…Cell surface expression levels of GPRC5D, an orphan G protein–coupled receptor, are significantly higher on multiple myeloma (MM) cells, compared with normal…”
Get full text

Preclinical Activity of JNJ-7957, a Novel BCMA×CD3 Bispecific Antibody for the Treatment of Multiple Myeloma, Is Potentiated by Daratumumab by Frerichs, Kristine A, Broekmans, Marloes E C, Marin Soto, Jhon A, van Kessel, Berris, Heymans, Martijn W, Holthof, Lisa C, Verkleij, Christie P M, Boominathan, Rengasamy, Vaidya, Bhavesh, Sendecki, Jocelyn, Axel, Amy, Gaudet, Francois, Pillarisetti, Kodandaram, Zweegman, Sonja, Adams, 3rd, Homer C, Mutis, Tuna, van de Donk, Niels W C J

“…Multiple myeloma (MM) patients with disease refractory to all available drugs have a poor outcome, indicating the need for new agents with novel mechanisms of…”
Get full text

Preclinical Rationale for Targeting the PD-1/PD-L1 Axis in Combination with a CD38 Antibody in Multiple Myeloma and Other CD38-Positive Malignancies by Verkleij, Christie P M, Jhatakia, Amy, Broekmans, Marloes E C, Frerichs, Kristine A, Zweegman, Sonja, Mutis, Tuna, Bezman, Natalie A, van de Donk, Niels W C J

“…The CD38-targeting antibody daratumumab mediates its anti-myeloma activities not only through Fc-receptor-dependent effector mechanisms, but also by its…”
Get full text

NK Cell Phenotype Is Associated With Response and Resistance to Daratumumab in Relapsed/Refractory Multiple Myeloma by Verkleij, Christie P.M., Frerichs, Kristine A., Broekmans, Marloes E.C., Duetz, Carolien, O'Neill, Chloe A., Bruins, Wassilis S.C., Homan‐Weert, Paola M., Minnema, Monique C., Levin, Mark‐David, Broijl, Annemiek, Bos, Gerard M.J., Kersten, Marie José, Klein, Saskia K., Shikhagaie, Medya M., Casneuf, Tineke, Abraham, Yann, Smets, Tina, Vanhoof, Greet, Cortes‐Selva, Diana, Steenbergen, Laure, Ramos, Elena, Verona, Raluca I., Krevvata, Maria, Sonneveld, Pieter, Zweegman, Sonja, Mutis, Tuna, Donk, Niels W.C.J.

“…The CD38‐targeting antibody daratumumab has marked activity in multiple myeloma (MM). Natural killer (NK) cells play an important role during daratumumab…”
Get full text

Anti-human Vascular Endothelial Growth Factor (VEGF) Antibody Selection for Immunohistochemical Staining of Proliferating Blood Vessels by van der Loos, Chris M, Meijer-Jorna, Lorine B, Broekmans, Marloes E.C, Ploegmakers, Hanneke P.H.M, Teeling, Peter, de Boer, Onno J, van der Wal, Allard C

“…Nine commercially available vascular endothelial growth factor (VEGF) antibodies were investigated for their ability to immunostain vascular malformations…”
Get full text

CD38-targeting antibodies in multiple myeloma: mechanisms of action and clinical experience by Frerichs, Kristine A, Nagy, Noemi Anna, Lindenbergh, Pieter L, Bosman, Patty, Marin Soto, Jhon, Broekmans, Marloes, Groen, Richard W J, Themeli, Maria, Nieuwenhuis, Louise, Stege, Claudia, Nijhof, Inger S, Mutis, Tuna, Zweegman, Sonja, Lokhorst, Henk M, van de Donk, Niels W C J

“…Multiple myeloma (MM) is generally an incurable hematological malignancy with heterogeneous overall survival rates ranging from a few months to more than…”
Get more information

Neuroblastoma is composed of two super-enhancer-associated differentiation states by van Groningen, Tim, Koster, Jan, Valentijn, Linda J, Zwijnenburg, Danny A, Akogul, Nurdan, Hasselt, Nancy E, Broekmans, Marloes, Haneveld, Franciska, Nowakowska, Natalia E, Bras, Johannes, van Noesel, Carel J M, Jongejan, Aldo, van Kampen, Antoine H, Koster, Linda, Baas, Frank, van Dijk-Kerkhoven, Lianne, Huizer-Smit, Margriet, Lecca, Maria C, Chan, Alvin, Lakeman, Arjan, Molenaar, Piet, Volckmann, Richard, Westerhout, Ellen M, Hamdi, Mohamed, van Sluis, Peter G, Ebus, Marli E, Molenaar, Jan J, Tytgat, Godelieve A, Westerman, Bart A, van Nes, Johan, Versteeg, Rogier

“…Rogier Versteeg, Johan van Nes and colleagues report that neuroblastomas comprise two cell types, mesenchymal and adrenergic, that have different responses to…”
Get full text

LIN28B induces neuroblastoma and enhances MYCN levels via let-7 suppression by Molenaar, Jan J, Domingo-Fernández, Raquel, Ebus, Marli E, Lindner, Sven, Koster, Jan, Drabek, Ksenija, Mestdagh, Pieter, van Sluis, Peter, Valentijn, Linda J, van Nes, Johan, Broekmans, Marloes, Haneveld, Franciska, Volckmann, Richard, Bray, Isabella, Heukamp, Lukas, Sprüssel, Annika, Thor, Theresa, Kieckbusch, Kristina, Klein-Hitpass, Ludger, Fischer, Matthias, Vandesompele, Jo, Schramm, Alexander, van Noesel, Max M, Varesio, Luigi, Speleman, Frank, Eggert, Angelika, Stallings, Raymond L, Caron, Huib N, Versteeg, Rogier, Schulte, Johannes H

“…Jan Molenaar and colleagues show that LIN28B is overexpressed and amplified in human neuroblastomas and that LIN28B regulates let-7 family miRNAs and MYCN…”
Get full text

Mechanisms of Resistance and Determinants of Response of the GPRC5D-Targeting T-Cell Redirecting Bispecific Antibody JNJ-7564 in Multiple Myeloma by Verkleij, Christie P.M., Broekmans, Marloes, Wong, Amy, Zweegman, Sonja, Verona, Raluca, Adams, Homer, Mutis, Tuna, van de Donk, Niels W.C.J.

“…Introduction: New immunotherapies directed against CD38, SLAMF7 or BCMA have significantly improved the outcome of multiple myeloma (MM) patients. However,…”
Get full text

T-cell redirecting bispecific antibodies targeting BCMA for the treatment of multiple myeloma by Verkleij, Christie P M, Frerichs, Kristine A, Broekmans, Marloes, Absalah, Saida, Maas-Bosman, Patricia W C, Kruyswijk, Sandy, Nijhof, Inger S, Mutis, Tuna, Zweegman, Sonja, van de Donk, Niels W C J

“…B-cell maturation antigen (BCMA)-targeting bispecific antibodies and bispecific T-cell engagers (BiTEs) redirect T-cells to BCMA-expressing multiple myeloma…”
Get full text

Preclinical evaluation of the new GPRC5DxCD3 (JNJ-7564) bispecific antibody for the treatment of multiple myeloma by Verkleij, Christie, Broekmans, Marloes, van Duin, Mark, Frerichs, Kristine, Kuiper, Rowan, Kaiser, Martin, Morgan, Gareth, Axel, Amy, Chiu, Chris, Sonneveld, Pieter, Zweegman, Sonja, Adams, Homer, Mutis, Tuna, Van de Donk, Niels

Get full text

Abstract LB-209: Neuroblastoma is biphasic with classical neuro-epithelial cells and chemoresistant mesenchymal cells controlled by PRRX1-NOTCH signaling by Groningen, Tim van, Nowakowska, Natalia E., Akogul, Nurdan, Broekmans, Marloes, Bras, Johannes, Booij, Jan, Ebus, Marli E., Molenaar, Jan J., Westerhout, Ellen M., Hamdi, Mohamed, Sluis, Peter van, Koster, Jan, Westerman, Bart A., Tytgat, Godelieve A., Versteeg, Rogier, Nes, Johan van

“…Abstract Most high stage neuroblastoma initially respond to chemotherapy, but ultimately relapse as therapy-resistant tumor. The mechanisms driving relapse and…”
Get full text